Atara Biotherapeutics Inc (ATRA) has disclosed a new risk, in the Accounting & Financial Operations category.
Atara Biotherapeutics Inc. faces substantial business risk as it struggles to achieve profitability with limited revenue from the commercialization of its sole approved product, Ebvallo. Under the A&R Commercialization and HCRx Agreements, long-term profitability is contingent upon its partners’ ability to effectively market and sell products, navigate regulatory landscapes, and secure adequate reimbursement. Additionally, the company’s future revenue streams are uncertain, as they are tied to the successful commercialization efforts of partners and meeting the royalty cap under the HCRx Agreement. The potential for profitability is further challenged by market acceptance, competitive pressures, and the need for ongoing funding to sustain operations.
Overall, Wall Street has a Moderate Buy consensus rating on ATRA stock based on 2 Buys and 1 Hold.
To learn more about Atara Biotherapeutics Inc’s risk factors, click here.
